Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
在 III 期随机、安慰剂对照试验中，评估了 dostarlimab 与化疗联合治疗原发性晚期或复发性子宫内膜癌患者的安全性 (ENGOT-EN6-NSGO/GOG-3031/RUBY)
期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359241277656
Auranen, Annika; Powell, Matthew A; Sukhin, Vladyslav; Landrum, Lisa M; Ronzino, Graziana; Buscema, Joseph; Bauerschlag, Dirk; Lalisang, Roy; Bender, David; Gilbert, Lucy; Armstrong, Amy; Safra, Tamar; Nevadunsky, Nicole; Sebastianelli, Alexandra; Slomovitz, Brian; Ring, Kari; Coleman, Robert; Podzielinski, Iwona; Stuckey, Ashley; Teneriello, Michael; Gill, Sarah; Pothuri, Bhavana; Willmott, Lyndsay; Sharma, Sudarshan; Dabrowski, Christine; Antony, Grace; Stevens, Shadi; Mirza, Mansoor Raza; Fleming, Evelyn
